 |
24 Diseases |  |
14 Trials |
|
14 Trials |  |
566 News |  |
| «12345678» |
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, lamivudine / Generic Mfg.
Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1903;
Coformulated E/C/F/TAF achieved high rate of HBV viral suppression in HIV/HBV-coinfected patient with either lamivudine-resistant or lamivudine-susceptible HBV. A significant decrease in HBsAg level and a higher rate of HBeAg loss were observed in patients with lamivudine-susceptible HBV than those with lamivudine-resistant HBV.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1884;
E/C/F/TAF achieved both HBV and HIV viral suppression in HIV/HBV-coinfected participants. Switch to E/C/F/TAF resulted in less proteinuria, improved BMD of the lumbar spine and hip, but increased lipids at Week 48.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1764;
Through W48, high rates of virologic suppression were maintained in older participants who switched to B/F/TAF. The safety and efficacy data support the switch to B/F/TAF in virologically suppressed HIV-infected individuals aged ≥ 65 years.
- bictegravir (GS-9883) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, abacavir/lamivudine / Generic Mfg.
Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1693;
Our study supports existing evidence that DTG/3TC/ABC is associated with neuropsychiatric AEs that improve after switching to EVG/c/FTC/TAF and confirms the improvement observed in neuropsychiatric symptomatology in some cohorts after DTG/3TC/ABC discontinuation and in the GS-US-380-1844 clinical trial after switching to bictegravir/FTC/TAF. [Changes in neuropsychiatric scores after switching to E/C/F/TAF ]
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1690;
P3
[Changes in neuropsychiatric scores after switching to E/C/F/TAF ] Changes in HIV-DNA from baseline to W48 in virologically suppressed individuals who switch from a 2DR with DTG+1RTI to E/C/F/TAF did not significantly differ from changes in those who continue with the ongoing 2DR.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1686;
Switching to E/C/F/TAF was associated with stable renal functions. Its use was associated with increases in LDL-cholesterol, triglycerides and also in HDL cholesterol levels at month 6; these effects were diminished at month 12.
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study) (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1681;
Although not recommended from guidelines, starting ART with an intensified quadruple regimen in patients with PHI has represented a clinical practice in recent years. In those patients an early switch to E/C/F/TAF showed to be effective in maintaining virologic control, reducing low level viral replication and in continuing immunological recovery.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1676;
This virological effectiveness was unaffected by baseline HIV RNA and CD4 levels. [Figure 1.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1664;
In total, 101 case patients with known M184V/I mutations were identified, including 6 (5.9%) with K65R and 19 (18.9%) with at least 1 TAM, and were matched to 404 controls in terms of age (mean, 41.3 vs 40.1 years), gender (male, 98.0% vs 98.0%) and cumulative exposure duration to tenofovir disoproxil fumarate (median, 138 vs 140 weeks). Among virally suppressed HIV-positive patients, E/C/F/TAF is effective in maintaining viral suppression at week 24 despite archived M184V/I mutations with or without TAMs.
- Prezista (darunavir) / J&J, ritonavir / Generic Mfg.
Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1644;
In this “real-world” cohort of MTR-treated patients, switching to a TAF-based STR plus boosted PI maintained virologic control in 97% of patients and was well-tolerated, supporting potential use of this strategy for regimen simplification. [FIGURE 1-Virologic Outcomes through Week 60 ]
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1633;
Overall persistence on F/TAF-based regimens was high in treatment-experienced PLHIV: >80% during 24 months of observation. Virologic effectiveness and safety were illustrated in a real world setting with < 5% discontinuations due to ADRs and < 2% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1632;
In the prospective French TARANIS cohort, persistence to E/C/F/TAF was high in TN and TE patients during the first year. Virologic effectiveness and safety of using E/C/F/TAF were confirmed in a real world setting with 7.4% discontinuations due to ADRs (not related to kidney or bone) and < 1% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1630;
In TE patients who switched from tenofovir disoproxil fumarate (TDF) to TAF, fasting lipid values increased compared to baseline while total/HDL cholesterol ratio did not change significantly. E/C/F/TAF had a high virological efficacy in both TN and TE patients and was tolerated very well.
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naïve HIV-1 infected patients - 24-month results from the German TAFNES cohort study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1621;
Overall virologic effectiveness was >80% two years after treatment initiation with only 2% virologic failure and low discontinuation rates (< 4%) due to ADRs. Improvements in self-reported HRQL and symptoms after 24 months of treatment illustrate the safety and effectiveness of F/TAF-based regimens in clinical routine care.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, abacavir/lamivudine / Generic Mfg.
A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1556;
E/C/F/TAF offers an effective, well tolerated switch option for patients with M184V/I. These data on continued virologic suppression despite pre-existing resistance are encouraging and warrant further follow-up.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, lamivudine / Generic Mfg.
Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1093;
Coformulated E/C/F/TAF achieved high rate of HBV viral suppression in HIV/HBV-coinfected patient with either lamivudine-resistant or lamivudine-susceptible HBV. A significant decrease in HBsAg level and a higher rate of HBeAg loss were observed in patients with lamivudine-susceptible HBV than those with lamivudine-resistant HBV.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1074;
E/C/F/TAF achieved both HBV and HIV viral suppression in HIV/HBV-coinfected participants. Switch to E/C/F/TAF resulted in less proteinuria, improved BMD of the lumbar spine and hip, but increased lipids at Week 48.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_954;
Through W48, high rates of virologic suppression were maintained in older participants who switched to B/F/TAF. The safety and efficacy data support the switch to B/F/TAF in virologically suppressed HIV-infected individuals aged ≥ 65 years.
- bictegravir (GS-9883) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, abacavir/lamivudine / Generic Mfg.
Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_883;
Our study supports existing evidence that DTG/3TC/ABC is associated with neuropsychiatric AEs that improve after switching to EVG/c/FTC/TAF and confirms the improvement observed in neuropsychiatric symptomatology in some cohorts after DTG/3TC/ABC discontinuation and in the GS-US-380-1844 clinical trial after switching to bictegravir/FTC/TAF. [Changes in neuropsychiatric scores after switching to E/C/F/TAF ]
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_880;
P3
[Changes in neuropsychiatric scores after switching to E/C/F/TAF ] Changes in HIV-DNA from baseline to W48 in virologically suppressed individuals who switch from a 2DR with DTG+1RTI to E/C/F/TAF did not significantly differ from changes in those who continue with the ongoing 2DR.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_876;
Switching to E/C/F/TAF was associated with stable renal functions. Its use was associated with increases in LDL-cholesterol, triglycerides and also in HDL cholesterol levels at month 6; these effects were diminished at month 12.
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study) (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_871;
Although not recommended from guidelines, starting ART with an intensified quadruple regimen in patients with PHI has represented a clinical practice in recent years. In those patients an early switch to E/C/F/TAF showed to be effective in maintaining virologic control, reducing low level viral replication and in continuing immunological recovery.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_866;
This virological effectiveness was unaffected by baseline HIV RNA and CD4 levels. [Figure 1.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_854;
In total, 101 case patients with known M184V/I mutations were identified, including 6 (5.9%) with K65R and 19 (18.9%) with at least 1 TAM, and were matched to 404 controls in terms of age (mean, 41.3 vs 40.1 years), gender (male, 98.0% vs 98.0%) and cumulative exposure duration to tenofovir disoproxil fumarate (median, 138 vs 140 weeks). Among virally suppressed HIV-positive patients, E/C/F/TAF is effective in maintaining viral suppression at week 24 despite archived M184V/I mutations with or without TAMs.
- Prezista (darunavir) / J&J, ritonavir / Generic Mfg.
Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_834;
In this “real-world” cohort of MTR-treated patients, switching to a TAF-based STR plus boosted PI maintained virologic control in 97% of patients and was well-tolerated, supporting potential use of this strategy for regimen simplification. [FIGURE 1-Virologic Outcomes through Week 60 ]
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_823;
Overall persistence on F/TAF-based regimens was high in treatment-experienced PLHIV: >80% during 24 months of observation. Virologic effectiveness and safety were illustrated in a real world setting with < 5% discontinuations due to ADRs and < 2% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_822;
In the prospective French TARANIS cohort, persistence to E/C/F/TAF was high in TN and TE patients during the first year. Virologic effectiveness and safety of using E/C/F/TAF were confirmed in a real world setting with 7.4% discontinuations due to ADRs (not related to kidney or bone) and < 1% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_820;
In TE patients who switched from tenofovir disoproxil fumarate (TDF) to TAF, fasting lipid values increased compared to baseline while total/HDL cholesterol ratio did not change significantly. E/C/F/TAF had a high virological efficacy in both TN and TE patients and was tolerated very well.
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naïve HIV-1 infected patients - 24-month results from the German TAFNES cohort study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_811;
Overall virologic effectiveness was >80% two years after treatment initiation with only 2% virologic failure and low discontinuation rates (< 4%) due to ADRs. Improvements in self-reported HRQL and symptoms after 24 months of treatment illustrate the safety and effectiveness of F/TAF-based regimens in clinical routine care.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, abacavir/lamivudine / Generic Mfg.
A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_746;
E/C/F/TAF offers an effective, well tolerated switch option for patients with M184V/I. These data on continued virologic suppression despite pre-existing resistance are encouraging and warrant further follow-up.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, lamivudine / Generic Mfg.
Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_628;
Coformulated E/C/F/TAF achieved high rate of HBV viral suppression in HIV/HBV-coinfected patient with either lamivudine-resistant or lamivudine-susceptible HBV. A significant decrease in HBsAg level and a higher rate of HBeAg loss were observed in patients with lamivudine-susceptible HBV than those with lamivudine-resistant HBV.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_609;
E/C/F/TAF achieved both HBV and HIV viral suppression in HIV/HBV-coinfected participants. Switch to E/C/F/TAF resulted in less proteinuria, improved BMD of the lumbar spine and hip, but increased lipids at Week 48.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, abacavir/lamivudine / Generic Mfg.
A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_340;
E/C/F/TAF offers an effective, well tolerated switch option for patients with M184V/I. These data on continued virologic suppression despite pre-existing resistance are encouraging and warrant further follow-up.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_261;
Through W48, high rates of virologic suppression were maintained in older participants who switched to B/F/TAF. The safety and efficacy data support the switch to B/F/TAF in virologically suppressed HIV-infected individuals aged ≥ 65 years.
- bictegravir (GS-9883) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, abacavir/lamivudine / Generic Mfg.
Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_135;
Our study supports existing evidence that DTG/3TC/ABC is associated with neuropsychiatric AEs that improve after switching to EVG/c/FTC/TAF and confirms the improvement observed in neuropsychiatric symptomatology in some cohorts after DTG/3TC/ABC discontinuation and in the GS-US-380-1844 clinical trial after switching to bictegravir/FTC/TAF. [Changes in neuropsychiatric scores after switching to E/C/F/TAF ]
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_132;
P3
[Changes in neuropsychiatric scores after switching to E/C/F/TAF ] Changes in HIV-DNA from baseline to W48 in virologically suppressed individuals who switch from a 2DR with DTG+1RTI to E/C/F/TAF did not significantly differ from changes in those who continue with the ongoing 2DR.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_128;
Switching to E/C/F/TAF was associated with stable renal functions. Its use was associated with increases in LDL-cholesterol, triglycerides and also in HDL cholesterol levels at month 6; these effects were diminished at month 12.
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study) (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_123;
Although not recommended from guidelines, starting ART with an intensified quadruple regimen in patients with PHI has represented a clinical practice in recent years. In those patients an early switch to E/C/F/TAF showed to be effective in maintaining virologic control, reducing low level viral replication and in continuing immunological recovery.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_118;
This virological effectiveness was unaffected by baseline HIV RNA and CD4 levels. [Figure 1.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_106;
In total, 101 case patients with known M184V/I mutations were identified, including 6 (5.9%) with K65R and 19 (18.9%) with at least 1 TAM, and were matched to 404 controls in terms of age (mean, 41.3 vs 40.1 years), gender (male, 98.0% vs 98.0%) and cumulative exposure duration to tenofovir disoproxil fumarate (median, 138 vs 140 weeks). Among virally suppressed HIV-positive patients, E/C/F/TAF is effective in maintaining viral suppression at week 24 despite archived M184V/I mutations with or without TAMs.
- Prezista (darunavir) / J&J, ritonavir / Generic Mfg.
Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_86;
In this “real-world” cohort of MTR-treated patients, switching to a TAF-based STR plus boosted PI maintained virologic control in 97% of patients and was well-tolerated, supporting potential use of this strategy for regimen simplification. [FIGURE 1-Virologic Outcomes through Week 60 ]
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_75;
Overall persistence on F/TAF-based regimens was high in treatment-experienced PLHIV: >80% during 24 months of observation. Virologic effectiveness and safety were illustrated in a real world setting with < 5% discontinuations due to ADRs and < 2% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_74;
In the prospective French TARANIS cohort, persistence to E/C/F/TAF was high in TN and TE patients during the first year. Virologic effectiveness and safety of using E/C/F/TAF were confirmed in a real world setting with 7.4% discontinuations due to ADRs (not related to kidney or bone) and < 1% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_72;
In TE patients who switched from tenofovir disoproxil fumarate (TDF) to TAF, fasting lipid values increased compared to baseline while total/HDL cholesterol ratio did not change significantly. E/C/F/TAF had a high virological efficacy in both TN and TE patients and was tolerated very well.
- Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naïve HIV-1 infected patients - 24-month results from the German TAFNES cohort study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_63;
Overall virologic effectiveness was >80% two years after treatment initiation with only 2% virologic failure and low discontinuation rates (< 4%) due to ADRs. Improvements in self-reported HRQL and symptoms after 24 months of treatment illustrate the safety and effectiveness of F/TAF-based regimens in clinical routine care.
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis (clinicaltrials.gov) - Nov 13, 2019
P3b, N=55, Completed, Sponsor: Gilead Sciences
Improvements in self-reported HRQL and symptoms after 24 months of treatment illustrate the safety and effectiveness of F/TAF-based regimens in clinical routine care. Active, not recruiting --> Completed
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Early ART to Limit Infection and Establishment of Reservoir (clinicaltrials.gov) - Nov 11, 2019
P2, N=150, Recruiting, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Trial completion date: Jun 2020 --> May 2021 | Trial primary completion date: Dec 2019 --> Nov 2020
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date, Trial primary completion date: Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection (clinicaltrials.gov) - Oct 18, 2019
P=N/A, N=72, Recruiting, Sponsor: University of California, Los Angeles
Trial completion date: Jun 2020 --> May 2021 | Trial primary completion date: Dec 2019 --> Nov 2020 Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Feb 2020
- | Genvoya (elvitegravir+cobicistat+emtricitabine+tenofovir alafenamide) / Gilead, warfarin / Generic Mfg.
Clinical, Journal: Abnormal elevation of INR in a patient during the co-administration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: A case report. (Pubmed Central) - Oct 16, 2019
Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Feb 2020 No abstract available
- | Vitekta (elvitegravir) / Japan Tobacco, Gilead
Journal: Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. (Pubmed Central) - Oct 14, 2019
A switch to E/C/F/TDF or E/C/F/TAF is safe for virologically suppressed patients without documented NRTI resistance, but not recommended in viraemic patients with a history of NRTI resistance. Although we did not detect a detrimental effect of past NRTI resistance in virologically suppressed patients, a fully active regimen remains preferred in this setting due to possible rebound of drug-resistant virus in the long term.